Assessing the real-world impact of a low nicotine product standard for smoked tobacco in New Zealand

评估新西兰低尼古丁产品标准对吸食烟草的现实影响

基本信息

项目摘要

ABSTRACT A low nicotine product standard for cigarettes and other combusted tobacco products has been proposed as a cornerstone of the FDA’s Comprehensive Plan for Tobacco and Nicotine Regulation in the United States (US). This proposed standard is based largely on randomized clinical trials demonstrating that when people switch to very low nicotine content (VLNC) cigarettes, cigarettes per day, dependence and biomarkers of smoke exposure decrease and quit attempts and cessation increase. Yet, these trials have impo rtant limitations. Notably, they limit the duration of exposure to VLNC cigarettes; cannot recreate the complex context of real - world product standards; are characterized by the use of non-study, normal nicotine cigarettes; and generally focus on samples of convenience. In December 2021, the New Zealand (NZ) Government launched the Smokefree Aotearoa 2025 Action Plan, outlining a strategy to reduce smoking prevalence to less than 5%. The plan is world-leading with transformative goals including: 1) eliminate health inequities in smoking rates and smoking-related illness; 2) ensure youth never start smoking tobacco; and 3) increase quitting in people who smoke. A major component of the initiative is to mandate a low nicotine product standard for all smoked tobacco. Our primary research objective is to assess the real-world impact of a mandated reduction of nicotine in all smoked tobacco products in NZ to inform the implementation of US nicotine reduction policy. We propose to conduct a longitudinal, mixed methods cohort study of adults who smoke daily or nearly daily (N=1500), using online surveys, biomarkers of exposure, physiological assessments, qualitative interviews, and medical records to assess changes in smoking behavior, health and well-being. We will follow the cohort for 3.5 years (1.5 years before and 1 year after implementation of a low nicotine product standard). We will also explore potential heterogeneity by explicitly sampling individuals from three priority populations important in NZ and the US (individuals with self-reported anxiety and depression; young adults living in socioeconomically deprived areas; and individuals who report heavy alcohol and/or cannabis use) and ensuring representation of NZ ethnic groups (Māori, Pacifika) with disproportionately high smoking prevalence. We will also enroll people who smoke but do not belong to priority populations. The primary outcome for Aim 1 is abstinence from smoked tobacco (self-reported and biochemically-verified) at 52 weeks after policy implementation. The primary outcome for Aim 2 is Health-Related Quality of Life ratings at 52 weeks after policy implementation. Aim 3 will explore potential heterogeneity in response to a low nicotine products standard. Our proposal will directly inform the US nicotine reduction policy agenda recently announced by the Biden Administration and aligns with several priorities outlined in RFA-OD-21-002. As a team, we have complementary areas of expertise (e.g., behavioral pharmacology, public health and medicine, biostatistics, epidemiology, qualitative and mixed methods, and health equity) to ensure the successful completion of the current proposal.
摘要 已提议对香烟和其他燃烧的烟草产品实行低尼古丁产品标准, 这是FDA在美国(US)制定的烟草和尼古丁监管综合计划的基石。 这一标准的提出主要是基于随机临床试验,这些试验表明,当人们转向 极低尼古丁含量(VLNC)香烟,每日吸烟量,吸烟的依赖性和生物标志物 接触减少,戒烟尝试和戒烟增加。然而,这些试验具有重要的局限性。 值得注意的是,它们限制了暴露于VLNC香烟的持续时间;不能重现真实的的复杂背景- 世界产品标准;以使用非研究、正常尼古丁香烟为特征;一般 专注于方便的样品。2021年12月,新西兰政府推出了 《无烟奥特亚罗瓦2025行动计划》概述了将吸烟率降至5%以下的战略。的 该计划是世界领先的,其变革性目标包括:1)消除吸烟率方面的健康不平等, 吸烟相关疾病; 2)确保年轻人永远不会开始吸烟; 3)增加吸烟者的戒烟率, 抽烟该倡议的一个主要组成部分是强制所有吸烟者使用低尼古丁产品标准。 烟草我们的主要研究目标是评估强制减少尼古丁的现实影响 在新西兰的所有吸烟烟草产品中,为美国尼古丁减少政策的实施提供信息。我们提出 对每天或几乎每天吸烟的成年人(N=1500)进行纵向混合方法队列研究, 使用在线调查,暴露的生物标志物,生理评估,定性访谈和医疗 记录来评估吸烟行为、健康和福祉的变化。我们将对该队列进行为期3.5年的跟踪研究 (1.5实施低尼古丁产品标准前1年和实施低尼古丁产品标准后1年)。我们还将探索 潜在的异质性,明确抽样个人从三个重要的优先群体在新西兰和 美国(自我报告焦虑和抑郁的个人;生活在社会经济贫困地区的年轻人) 以及报告酗酒和/或吸食大麻的个人),并确保新西兰族裔 吸烟率高得不成比例的群体(毛利人、非裔毛利人)。我们还将招收 吸烟,但不属于优先人群。目标1的主要结局是戒烟 烟草(自我报告和生物化学验证)在政策实施后52周。主 目标2的结果是政策实施后52周的健康相关生活质量评级。目标3将 探索响应低尼古丁产品标准的潜在异质性。我们的建议将直接 告知拜登政府最近宣布的美国尼古丁减少政策议程,并与 RFA-OD-21-002中概述的几个优先事项。作为一个团队,我们拥有互补的专业领域(例如, 行为药理学,公共卫生和医学,生物统计学,流行病学,定性和混合 方法和卫生公平),以确保圆满完成目前的提案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERIC Christian DONNY其他文献

ERIC Christian DONNY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERIC Christian DONNY', 18)}}的其他基金

MARVEL: A Multidisciplinary Assessment of Risks from Vaping during Early Life
MARVEL:对生命早期电子烟风险的多学科评估
  • 批准号:
    10628250
  • 财政年份:
    2023
  • 资助金额:
    $ 72.02万
  • 项目类别:
Project 1 - Vaping Behavior, the Emergence of Dependence, and Well-being
项目 1 - 电子烟行为、依赖性的出现和幸福感
  • 批准号:
    10628251
  • 财政年份:
    2023
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    9149854
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    8545135
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
EFFECTS OF NICOTINE YIELD & NICOTINE REPLACEMENT ON VERY LOW NICOTINE CONTENT CIG
尼古丁产量的影响
  • 批准号:
    8153483
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    9889090
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    8710130
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    10578938
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    8153465
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:
Evaluating New Nicotine Standards for Cigarettes
评估卷烟新尼古丁标准
  • 批准号:
    8151825
  • 财政年份:
    2011
  • 资助金额:
    $ 72.02万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.02万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了